⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Inhibrx Biosciences, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Inhibrx Biosciences, Inc.
↗La Jolla, California, USA
Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on the development of engineered biologic therapeutics, particularly in oncology. The company was established in 2024 as a spin-off from the legacy Inhibrx, Inc. following Sanofi's acquisition of the INBRX-101 (efdoralprin alfa) program.
The company utilizes a proprietary protein-engineering platform to design multivalent biologics intended to achieve stronger receptor biology than standard monoclonal antibodies. Its current operations are focused on advancing its oncology pipeline, including lead candidates ozekibart (INBRX-109) and INBRX-106, while maintaining a lean, focused drug development model that outsources manufacturing and clinical execution.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2024
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:INBX
Market Cap:$1.36B
PIPELINE
Stage:Phase 2/3
Lead Drug Stage:Phase 3
Modalities:mAb, Engineered biologics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Merck & Co. (collaboration on INBRX-106 combination studies with Keytruda)
COMPETITION
Position:Emerging
Competitors:Actuate Therapeutics
LEADERSHIP
Key Executives:
Brendan P. Eckelman - CEO
LINKS
Website:inhibrx.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Inhibrx Biosciences, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.